Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500) and the Nasdaq (COMP:IND) ending the week in the ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite last ...
Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...
Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...
Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top ...
Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with ...
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback